Response to Pham et al., "More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence"

J Am Acad Dermatol. 2024 May;90(5):e175-e176. doi: 10.1016/j.jaad.2023.12.042. Epub 2024 Jan 5.
No abstract available

Keywords: atypical fibroxanthoma; censoring; competing risks; metastasis; pleomorphic dermal sarcoma; recurrence; survival analysis.

Publication types

  • Letter

MeSH terms

  • Histiocytoma, Malignant Fibrous* / diagnosis
  • Humans
  • Skin Neoplasms* / diagnosis